Skip to main content
Livermore
Livermore
ZHEN

ProShare Advisors LLC

SEC CIK
0001357955
Latest filing
Aug 11, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by ProShare Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q2 2026)
8,568
Value
$670.6K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of HALO by ProShare Advisors LLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20268,568$670.6K<0.1%−1,429−14.3%ReducedHolders
Q1 20269,997$646.1K<0.1%+88+0.9%AddedHolders
Q4 20259,909$666.9K<0.1%+767+8.4%AddedHolders
Q3 20259,142$670.5K<0.1%−923−9.2%ReducedHolders
Q2 202510,065$523.6K<0.1%−27,918−73.5%ReducedHolders
Q1 202537,983$2.42M<0.1%−9,131−19.4%ReducedHolders
Q4 202447,114$2.25M<0.1%+10,531+28.8%AddedHolders
Q3 202436,583$2.09M<0.1%+5,325+17.0%AddedHolders
Q2 202431,258$1.64M<0.1%−7,404−19.2%ReducedHolders
Q1 202438,662$1.57M<0.1%+1,794+4.9%AddedHolders
Q4 202336,868$1.36M<0.1%+4,249+13.0%AddedHolders
Q3 202332,619$1.25M<0.1%−962−2.9%ReducedHolders
Q2 202333,581$1.21M<0.1%+477+1.4%AddedHolders
Q1 202333,104$1.26M<0.1%−5,596−14.5%ReducedHolders
Q4 202238,700$2.20M<0.1%+2,448+6.8%AddedHolders
Q3 202236,252$1.43M<0.1%+423+1.2%AddedHolders
Q2 202235,829$1.58M<0.1%−18,389−33.9%ReducedHolders
Q1 202254,218$2.16M<0.1%−12,097−18.2%ReducedHolders
Q4 202166,315$2.67M<0.1%+4,651+7.5%AddedHolders
Q3 202161,664$2.51M<0.1%−10,593−14.7%ReducedHolders
Q2 202172,257$3.28M<0.1%+8,220+12.8%AddedHolders
Q1 202164,037$2.67M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.